May 04, 2011
Merck KGaA affiliates have agreed to pay $44.3 million to resolve a whistleblower's allegations that they bought off health care providers to promote or prescribe the multiple sclerosis drug Rebif, resulting in tainted Medicare and Medicaid claims, federal authorities announced Wednesday.